FlexShares Credit-Scored US Corporate Bond Index Fund Price & Performance (SKOR)

The FlexShares Credit-Scored US Corporate Bond Index Fund (NASDAQ:SKOR) saw a significant rise in short interest, growing 61.5% in February to 4,200 shares. Despite this, its trading volume remains robust, with a days-to-cover ratio of just 0.1 days. Institutional investors have also been adjusting their positions in the fund.1

BioCryst Pharmaceuticals (NASDAQ:BCRX) is expected to post a Q1 2025 EPS of ($0.06), with analysts projecting profitability by Q3 2025. The company’s stock has shown resilience, trading at $8.47, and institutional investors continue to increase their holdings. Analysts maintain a consensus rating of 'Moderate Buy' with a $15.57 price target.2

Environmental, social, and governance (ESG) ETFs are attracting attention, with some funds like BNY Mellon Women's Opportunities ETF showing a 43.16% annual performance. ESG ETFs offer both financial returns and societal impact, and investors are increasingly considering them as a tool for sustainable investing while managing risk.3